B cell receptor (BCR) signalling has emerged as a therapeutic target in B cell lymphomas,
but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a …

Signals emanating from the B‐cell receptor (BCR) promote proliferation and survival in
diverse forms of B‐cell lymphoma. Precision medicine strategies targeting the BCR pathway …

Chronic active B cell receptor (BCR) signaling, a hallmark of the activated B cell-like (ABC)
subtype of diffuse large B cell lymphoma (DLBCL), engages the CARD11-MALT1-BCL10 …

The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) remains
the least curable form of this malignancy despite recent advances in therapy. Constitutive …

The aggressive activated B cell-like subtype of diffuse large B-cell lymphoma is
characterized by aberrant B-cell receptor (BCR) signaling and constitutive nuclear factor …

A role for B-cell-receptor (BCR) signalling in lymphomagenesis has been inferred by
studying immunoglobulin genes in human lymphomas, and by engineering mouse models …

The B-cell receptor (BCR) is essential for normal B-cell development and maturation. In an
increasing number of B-cell malignancies, BCR signaling is implicated as a pivotal pathway …

The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like
(ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC …

The importance of understanding the genetic and biochemical basis of B-cell receptor (BCR)
survival signaling in diffuse large B-cell lymphoma (DLBCL) is underscored by the recent …

Burkitt's lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of
such therapy precludes its use in the elderly and in patients with endemic BL in developing …